Legend Biotech Corp ADR (NASDAQ: LEGN)’s stock price has dropped by -3.78 in relation to previous closing price of 45.26. Nevertheless, the company has seen a loss of -12.74% in its stock price over the last five trading days. seekingalpha.com reported 2024-09-18 that Carvykti, a CAR-T therapy co-developed by Legend Biotech & J&J, is central to second-line multiple myeloma treatment. Both firms are actively scaling up production across bases. Carvykti sales surged 60% YoY, reaching US$343 million in 1H2024, forecasting US$1 bilion+ for the full year. Rumors since July claim Legend Biotech faced a takeover bid, with fresh whispers of pricing disputes in negotiations this week.
Is It Worth Investing in Legend Biotech Corp ADR (NASDAQ: LEGN) Right Now?
Company’s 36-month beta value is 0.10.Analysts have differing opinions on the stock, with 15 analysts rating it as a “buy,” 7 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LEGN is 181.45M, and currently, short sellers hold a 5.77% ratio of that floaft. The average trading volume of LEGN on September 26, 2024 was 924.41K shares.
LEGN’s Market Performance
LEGN stock saw a decrease of -12.74% in the past week, with a monthly decline of -23.10% and a quarterly a decrease of -2.99%. The volatility ratio for the week is 4.65%, and the volatility levels for the last 30 days are 4.11% for Legend Biotech Corp ADR (LEGN). The simple moving average for the past 20 days is -16.16% for LEGN’s stock, with a -19.15% simple moving average for the past 200 days.
Analysts’ Opinion of LEGN
Many brokerage firms have already submitted their reports for LEGN stocks, with Truist repeating the rating for LEGN by listing it as a “Buy.” The predicted price for LEGN in the upcoming period, according to Truist is $88 based on the research report published on June 17, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LEGN reach a price target of $73, previously predicting the price at $86. The rating they have provided for LEGN stocks is “Buy” according to the report published on May 24th, 2024.
Deutsche Bank gave a rating of “Buy” to LEGN, setting the target price at $60 in the report published on May 23rd of the current year.
LEGN Trading at -20.51% from the 50-Day Moving Average
After a stumble in the market that brought LEGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.47% of loss for the given period.
Volatility was left at 4.11%, however, over the last 30 days, the volatility rate increased by 4.65%, as shares sank -23.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.09% lower at present.
During the last 5 trading sessions, LEGN fell by -12.74%, which changed the moving average for the period of 200-days by -29.09% in comparison to the 20-day moving average, which settled at $51.27. In addition, Legend Biotech Corp ADR saw -27.62% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LEGN starting from Huang Ying, who proposed sale 1,504 shares at the price of $44.10 back on Sep 25 ’24. After this action, Huang Ying now owns shares of Legend Biotech Corp ADR, valued at $66,326 using the latest closing price.
Macomber Lori, the Officer of Legend Biotech Corp ADR, proposed sale 90,060 shares at $48.91 during a trade that took place back on Sep 20 ’24, which means that Macomber Lori is holding shares at $4,405,003 based on the most recent closing price.
Stock Fundamentals for LEGN
Current profitability levels for the company are sitting at:
- -0.76 for the present operating margin
- 0.57 for the gross margin
The net margin for Legend Biotech Corp ADR stands at -0.63. The total capital return value is set at -0.23. Equity return is now at value -22.21, with -15.29 for asset returns.
Based on Legend Biotech Corp ADR (LEGN), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -0.47. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is -15.49.
Currently, EBITDA for the company is -421.76 million with net debt to EBITDA at -0.42. When we switch over and look at the enterprise to sales, we see a ratio of 17.79. The receivables turnover for the company is 4.5for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.84.
Conclusion
In a nutshell, Legend Biotech Corp ADR (LEGN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
